Urolithin A vs Pterostilbene
Urolithin A and pterostilbene often appear together in longevity supplement stacks, which can make them seem interchangeable. They are not. Urolithin A is a gut-derived postbiotic studied for supporting mitophagy, the recycling of worn-out mitochondria. Pterostilbene is a plant stilbene — a more bioavailable cousin of resveratrol — studied mainly for signaling pathways tied to metabolism. This is a calm, evidence-first look at how the two differ and where each one honestly stands.
The one-line distinction
Urolithin A supports a specific cellular housekeeping process; pterostilbene is a polyphenol signaling molecule in the resveratrol family. Mitophagy, the process urolithin A engages, clears out damaged mitochondria so healthier ones can take over. Pterostilbene is studied for activating pathways such as sirtuins and AMPK that are involved in how cells sense energy and stress. Both touch the biology of aging, but they pull different levers, and the human evidence behind them is at very different stages.
New to the first compound? Start with our complete urolithin A guide, and if the mitochondrial angle is what draws you, the explainer on what mitophagy is unpacks the exact process urolithin A supports.
What pterostilbene is
Pterostilbene is a naturally occurring stilbene found in blueberries, grapes and certain nuts. Structurally it is closely related to resveratrol, the famous compound associated with red wine, but with a key chemical difference: pterostilbene carries two methoxy groups in place of resveratrol’s hydroxyl groups. That change makes the molecule more fat-soluble, which in practice tends to give it markedly better oral bioavailability and a longer half-life in the body than resveratrol. In other words, pterostilbene is often positioned as the more absorbable version of the resveratrol idea.
What the evidence for pterostilbene looks like
It is worth being straightforward: most of the enthusiasm for pterostilbene rests on preclinical work — cell and animal studies exploring antioxidant activity, metabolic signaling and sirtuin-related pathways. Human data exist but are limited. One frequently cited human trial found that pterostilbene influenced blood pressure and cholesterol markers, with a signal that higher doses could raise LDL cholesterol in some participants, which is exactly the kind of nuance that argues for medical oversight rather than casual high-dose use. The short version is that pterostilbene is a promising research compound whose human evidence base is still early and, in places, mixed. It is not a treatment for any disease.
What urolithin A is
Urolithin A is a postbiotic produced by gut bacteria when they break down ellagitannins, the polyphenols in pomegranates, walnuts and certain berries. The practical catch is that only some people carry the microbiome needed to convert those polyphenols into meaningful amounts of urolithin A, so the source foods do not reliably produce it in everyone. Supplementing directly removes that variability and delivers a consistent dose.
Its studied mechanism is support for mitophagy. Mitochondria are the cell’s power plants, and they gradually accumulate damage. Mitophagy identifies and clears the worn ones so the cell can keep a healthier working population — a process that slows with age and that urolithin A is one of the few dietary compounds shown to engage.
Proven human evidence for urolithin A
The human record begins with Andreux and colleagues (2019, Nature Metabolism), the first-in-human study, which reported urolithin A as safe and well tolerated at doses up to 1,000 mg per day alongside a mitochondrial gene-expression signature. Liu and D’Amico and colleagues (2022, JAMA Network Open) studied older adults over roughly four months and observed effects on muscle endurance. Singh and colleagues (2022, Cell Reports Medicine) tested 500 mg and 1,000 mg arms in middle-aged adults over four months, reporting benefits for muscle strength and exercise performance.
Newer human evidence
Recent trials have widened the picture. A 2025 randomized controlled trial in Nature Aging (about 28 days) reported that urolithin A supported the mitochondrial health of immune cells in midlife adults, a line of work linked to inflammaging. A 2024 trial in the Journal of the International Society of Sports Nutrition ran eight weeks in resistance-trained men, and a 2025 trial studied distance runners. As the 2024 systematic review in Ageing Research Reviews concluded, this is a growing but still-emerging body of human evidence.
Preclinical urolithin A research
The mechanistic groundwork comes from laboratory studies that should be read as preclinical. Ryu and colleagues (2016, Nature Medicine) demonstrated mitophagy, extended lifespan in the worm C. elegans, and muscle benefits in rodents. D’Amico and colleagues (2022, Aging Cell) explored joint and cartilage outcomes in osteoarthritis models. Areas like skin, gut, brain and heart are still early and exploratory, where preclinical research is investigating possibilities not yet confirmed in humans.
Mitophagy vs a stilbene: how they compare
The cleanest contrast is one of mechanism plus evidence maturity. Pterostilbene is a signaling polyphenol; its appeal is that it is a more absorbable take on the resveratrol concept, and its story is largely preclinical with a handful of small, mixed human studies. Urolithin A is a mitophagy-supporting postbiotic with several published randomized human trials behind specific structure/function observations in muscle and mitochondrial biology. So while both are studied in the context of healthy aging, they are not doing the same thing, and urolithin A currently rests on a more developed set of human trials.
There is also a bioavailability angle worth naming. Pterostilbene’s selling point over resveratrol is absorption. With urolithin A, the analogous problem is not absorption of the molecule but whether your body makes it at all — the microbiome conversion issue — which is precisely what direct supplementation is designed to solve. Different problems, different solutions.
Dosing and practical notes
Urolithin A has been studied at 500 to 1,000 mg per day, with 1,000 mg at the top of the range and the dose SOMA HEALTH Urolithin A Gummies are built around; our dosage page goes deeper. Pterostilbene has no firmly established supplemental dose, human trials have used a range of amounts, and because at least one study raised a question about LDL cholesterol at higher intakes, it is a compound where checking the current label and consulting a clinician makes particular sense. If you are curious about how quickly any of this might matter, our page on how long urolithin A takes to work sets realistic expectations for the urolithin A side.
Neither compound is a treatment for any medical condition. If you are managing a metabolic, cardiovascular or other health concern, these ingredients are not a substitute for care. Talk with a qualified healthcare provider before starting either, especially if you take medication or have a health condition.
Which should you choose?
If you want the compound with the more developed human trial base for supporting mitochondrial quality control, urolithin A is the stronger evidence-backed pick today, and supplementing it directly sidesteps the microbiome lottery. If pterostilbene interests you, treat it as an earlier-stage research compound, favor the studied lower end of any dose range, and keep your clinician in the loop given the cholesterol nuance. Because the two act on different pathways, they are sometimes stacked rather than swapped. To compare specific urolithin A products on dose, testing and value, see our roundup of the best urolithin A gummies.
Frequently asked questions
Is pterostilbene the same as resveratrol?
No, but they are close relatives. Pterostilbene is a methylated form of resveratrol that tends to be more fat-soluble, giving it better oral bioavailability and a longer half-life. Its effects are still largely studied in preclinical models.
Which has stronger human evidence, urolithin A or pterostilbene?
Urolithin A currently has the more developed human trial base, including randomized studies on muscle and mitochondrial biology. Pterostilbene’s human data are more limited and in places mixed.
Can I take urolithin A and pterostilbene together?
They act through different pathways and are sometimes combined in stacks. There is no known direct conflict, but if you take medication or have a health condition, confirm with your healthcare provider first.
Why supplement urolithin A rather than eat pomegranates?
Only some people carry the gut bacteria that convert the ellagitannins in those foods into meaningful urolithin A. Direct supplementation delivers a consistent dose regardless of your microbiome.
What dose of urolithin A is studied?
Human trials have used 500 to 1,000 mg per day. SOMA HEALTH Urolithin A Gummies provide 1,000 mg per daily serving, the top of that studied range.
Do these compounds slow aging or treat disease?
No. Both are studied for structure/function support, not to diagnose, treat, cure or prevent any disease. For any medical concern, consult a qualified healthcare provider.
Shop SOMA HEALTH Urolithin A Gummies
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.
A clinically studied 1,000 mg dose of Urolithin A in one simple daily gummy — to support mitophagy, muscle strength, and cellular energy.
Shop SOMA Urolithin A Gummies →